Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer

This trial is testing whether a personalized cancer vaccine, combined with an immunotherapy drug and chemotherapy, can help prevent pancreatic cancer from coming back after surgery. The vaccine is designed using the patient's own tumor to target cancer cells that may remain after the operation. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) - Your tumor was completely removed with surgery (called an R0 resection), and the cancer was stage I–III - You did not receive chemotherapy or radiation before surgery - Your blood counts and organ function are in an acceptable range **You may NOT be eligible if...** - You received chemotherapy, radiation, or immunotherapy within 2 weeks before the first vaccine dose - You have had another cancer in the past 5 years (some exceptions apply) - You have an uncontrolled infection, heart condition, HIV, or active hepatitis B or C - You have an autoimmune disease or are on medications that suppress your immune system - You are pregnant or breastfeeding - You have had a severe reaction to a vaccine in the past Talk to your doctor to see if this trial is right for you.